Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1952 1
1962 1
1963 1
1964 1
1965 1
1966 1
1967 1
1968 1
1969 2
1970 5
1971 2
1972 5
1973 4
1974 6
1975 5
1976 11
1977 6
1978 9
1979 10
1980 10
1981 10
1982 13
1983 24
1984 10
1985 18
1986 22
1987 18
1988 30
1989 26
1990 31
1991 41
1992 50
1993 52
1994 56
1995 65
1996 96
1997 81
1998 94
1999 106
2000 121
2001 125
2002 146
2003 191
2004 183
2005 218
2006 257
2007 229
2008 259
2009 253
2010 287
2011 331
2012 340
2013 398
2014 397
2015 447
2016 477
2017 482
2018 549
2019 521
2020 682
2021 763
2022 735
2023 667
2024 634
2025 486

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,844 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety of Testosterone-Replacement Therapy.
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Study Investigators. Lincoff AM, et al. Among authors: chan a. N Engl J Med. 2023 Jul 13;389(2):107-117. doi: 10.1056/NEJMoa2215025. Epub 2023 Jun 16. N Engl J Med. 2023. PMID: 37326322 Clinical Trial.
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
Malec L, Peyvandi F, Chan AKC, Königs C, Zulfikar B, Yuan H, Simpson M, Álvarez Román MT, Carcao M, Staber JM, Dunn AL, Chou SC, d'Oiron R, Albisetti M, Demissie M, Santagostino E, Yarramaneni A, Wong N, Abad-Franch L, Gunawardena S, Fijnvandraat K; XTEND-Kids Trial Group. Malec L, et al. Among authors: chan akc. N Engl J Med. 2024 Jul 18;391(3):235-246. doi: 10.1056/NEJMoa2312611. N Engl J Med. 2024. PMID: 39018533 Clinical Trial.
Defining precancer: a grand challenge for the cancer community.
Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S; Precancer Think Tank Team. Faupel-Badger J, et al. Among authors: chan at. Nat Rev Cancer. 2024 Nov;24(11):792-809. doi: 10.1038/s41568-024-00744-0. Epub 2024 Oct 1. Nat Rev Cancer. 2024. PMID: 39354069 Review.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. Among authors: chan a. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Chan A, et al. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6. Clin Breast Cancer. 2021. PMID: 33183970 Free article. Clinical Trial.
CONSORT 2025 statement: updated guideline for reporting randomized trials.
Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. Hopewell S, et al. Among authors: chan aw. Nat Med. 2025 Jun;31(6):1776-1783. doi: 10.1038/s41591-025-03635-5. Epub 2025 Apr 15. Nat Med. 2025. PMID: 40229553 Review.
Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades.
Kirtane AR, Bi J, Rajesh NU, Tang C, Jimenez M, Witt E, McGovern MK, Cafi AB, Hatfield SJ, Rosenstock L, Becker SL, Machado N, Venkatachalam V, Freitas D, Huang X, Chan A, Lopes A, Kim H, Kim N, Collins JE, Howard ME, Manchkanti S, Hong TS, Byrne JD, Traverso G. Kirtane AR, et al. Among authors: chan a. Nat Biomed Eng. 2025 Feb 26. doi: 10.1038/s41551-025-01360-5. Online ahead of print. Nat Biomed Eng. 2025. PMID: 40011582
9,844 results